Evotec and Pfizer collaborate on metabolic and infectious diseases

""

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases.

The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics.

Dr Matthias Evers, Chief Business Officer at Evotec, commented: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec also contributes with its strong presence with more than 1,000 employees at our French sites, building a strong pipeline of medicines that matter. Focussing on diseases with severe unmet medical need and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.”

Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programmes.

Dr Luca Mollo, Vice President and Medical Lead France at Pfizer, said: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need.”

Earlier this year, Evotec also agreed a partnership with Variant Bio, combining the latter’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free